Pharmatest is a CRO offering translational research services for diseases with unmet clinical needs. We offer full-service research solutions for early drug development. Our focus is on preclinical efficacy models in the fields of cancer and skeletal diseases ranging from in vitro cell culture assays to in vivo models. In addition, we provide model and assay development services for our customers.
Pharmatest has carefully designed specific study setups for testing new drug candidates according to regulatory guidelines of FDA and EMA. We also provide specially designed studies for testing biosimilars and functional foods that have less extensive regulatory requirements. Some of our models are applicable for safety testing of chemicals according to the requirements of the new EU-regulatory framework REACH.
We place special emphasis on the high clinical predictivity and quality of the data acquired. All research models that we offer have been fully optimized and validated with several years of extensive R&D work. We put special efforts in our R&D for developing more predictive cell culture models to decrease the need of animal testing in order to reduce costs of our customers and to improve animal welfare.
All work in Pharmatest is performed according to our internal Quality Assurance System and Standard Operating Procedures. Using our services translates to significantly lower efficacy-related failure rates in later stages of drug development.